BioSpace News Archive

Leap Therapeutics, Inc., a biotechnology company focused on developing targeted and immuno-oncology therapeutics, reported financial results for the second quarter ended June 30, 2020.

4D Molecular Therapeutics, a clinical-stage leader in the development of precision-guided AAV gene medicines based on directed evolution, announced that the U.S. Food and Drug Administration has granted Fast Track designation to 4D-310 for Fabry disease, a debilitating lysosomal storage disorder caused by a deficiency of alpha-galactosidase A enzyme activity.

Phase 2b Trial Design for BLU-5937 in Refractory Chronic Cough to be Announced in Q3 2020

Advanced pipeline focused on rare hematologic diseases and cancers, including reporting favorable single-dose data for FT-4202 in sickle cell disease (SCD) from a randomized, multi-center, placebo-controlled Phase 1 trial

AstraZeneca Ships FLUMIST ® QUADRIVALENT Vaccine in the US for 2020-2021 Flu Season Production increased in anticipation of higher demand due to COVID-19; Over 25% more US doses of the only nasal-spray vaccine to be available as soon as early August WILMINGTON, Del.--( BUSINESS WIRE )-- AstraZeneca today announced the first shipment of FLUMIST ® QUADRIVALENT (Influenza Vaccine Live, Intranasal) doses in the US for the 2020-2021 influenza season. F

AzurRx BioPharma, Inc. (NASDAQ:AZRX) (“AzurRx” or the “Company”), a company specializing in the development of non-systemic, recombinant therapies for gastrointestinal diseases, today announced that is has enrolled the first three patients in its Phase 2b OPTION 2 clinical trial to investigate MS1819 in cystic fibrosis (C

Biocept, Inc . (Nasdaq: BIOC), a leading commercial provider of molecular technologies designed to provide physicians with clinically actionable information to improve outcomes, announces it has entered into an agreement with a healthcare group

--Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 for Patients with Advanced Solid Tumors Harboring a KRAS G12C Mutation--

Certara ® , the global leader in biosimulation, has launched an international registry of healthcare workers to collect information on risk factors for developing COVID-19 and the use of preventative therapies. The International Registry of Healthcare Workers Exposed to COVID-19 (UNITY Global) will enable prevention policies to be

Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW) (OTCQB: AGNPF) (the “ Company ” or “ Algernon ”) a clinical stage pharmaceutical development company, is pleased to announce that it has enrolled its first patient from the U.S. for its multinational Phase 2b/3 human study of NP-120 (Ifenprodil) for the treatment of COVID-19. The Company is also pleased to announce that it has now enrolled 26 patients since the study began